FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386753453> ?p ?o ?g. }

• W4386753453 abstract "In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance + best supportive care (BSC) prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (advanced UC) without progression after first-line platinum-based chemotherapy.To report post hoc analyses of subgroups defined by the duration of first-line chemotherapy and interval before maintenance.Patients with advanced UC without progression after four to six cycles of platinum-based chemotherapy and a 4-10-wk interval after chemotherapy (n = 700) were randomized to receive avelumab + BSC or BSC alone. Subgroups were defined by duration (quartile [Q]) and estimated number of cycles of chemotherapy, and interval between chemotherapy and maintenance. The median follow-up was >19 mo in both arms.OS (primary endpoint), PFS, and safety were assessed.Hazard ratios (95% confidence interval) for OS with avelumab + BSC versus BSC alone were as follows: by chemotherapy duration-<Q1: 0.65 (0.42-1.02), Q1-Q2: 0.79 (0.50-1.27), Q2-Q3: 0.74 (0.50-1.10), and >Q3: 0.63 (0.39-1.00); by number of cycles-four cycles: 0.69 (0.48-1.00), five cycles: 0.98 (0.57-1.71), and six cycles: 0.66 (0.47-0.92); and by interval-4-<6 wk: 0.75 (0.54-1.04), 6-<8 wk: 0.67 (0.43-1.06), and 8-10 wk: 0.69 (0.47-1.02). Results were similar for PFS. Safety was similar across subgroups. All analyses were exploratory.Post hoc analyses of OS and PFS in subgroups defined by first-line chemotherapy duration and interval before maintenance were generally consistent with the results in the overall population, with similar safety findings. Prospective trials are warranted to confirm these findings.Avelumab maintenance treatment helped patients with advanced urothelial cancer without disease progression after at least four cycles of prior chemotherapy, and who started maintenance treatment at least 4 wk after chemotherapy, to live longer." @default.
• W4386753453 created "2023-09-15" @default.
• W4386753453 creator A5002541288 @default.
• W4386753453 creator A5003798935 @default.
• W4386753453 creator A5004985848 @default.
• W4386753453 creator A5012800133 @default.
• W4386753453 creator A5015679960 @default.
• W4386753453 creator A5016654748 @default.
• W4386753453 creator A5017229890 @default.
• W4386753453 creator A5026717218 @default.
• W4386753453 creator A5027892519 @default.
• W4386753453 creator A5027991868 @default.
• W4386753453 creator A5036848171 @default.
• W4386753453 creator A5037677450 @default.
• W4386753453 creator A5044972820 @default.
• W4386753453 creator A5048855238 @default.
• W4386753453 creator A5050042851 @default.
• W4386753453 creator A5057146015 @default.
• W4386753453 creator A5060661714 @default.
• W4386753453 creator A5063795761 @default.
• W4386753453 creator A5074756323 @default.
• W4386753453 creator A5088582666 @default.
• W4386753453 date "2023-09-01" @default.
• W4386753453 modified "2023-10-16" @default.
• W4386753453 title "Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance" @default.
• W4386753453 cites W2789502254 @default.
• W4386753453 cites W2883565725 @default.
• W4386753453 cites W2973437854 @default.
• W4386753453 cites W3087464965 @default.
• W4386753453 cites W3137251658 @default.
• W4386753453 cites W3209393335 @default.
• W4386753453 cites W4200026971 @default.
• W4386753453 cites W4212954739 @default.
• W4386753453 cites W4324136523 @default.
• W4386753453 cites W4366339435 @default.
• W4386753453 cites W4367296748 @default.
• W4386753453 doi "https://doi.org/10.1016/j.eururo.2023.08.001" @default.
• W4386753453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37714742" @default.
• W4386753453 hasPublicationYear "2023" @default.
• W4386753453 type Work @default.
• W4386753453 citedByCount "0" @default.
• W4386753453 crossrefType "journal-article" @default.
• W4386753453 hasAuthorship W4386753453A5002541288 @default.
• W4386753453 hasAuthorship W4386753453A5003798935 @default.
• W4386753453 hasAuthorship W4386753453A5004985848 @default.
• W4386753453 hasAuthorship W4386753453A5012800133 @default.
• W4386753453 hasAuthorship W4386753453A5015679960 @default.
• W4386753453 hasAuthorship W4386753453A5016654748 @default.
• W4386753453 hasAuthorship W4386753453A5017229890 @default.
• W4386753453 hasAuthorship W4386753453A5026717218 @default.
• W4386753453 hasAuthorship W4386753453A5027892519 @default.
• W4386753453 hasAuthorship W4386753453A5027991868 @default.
• W4386753453 hasAuthorship W4386753453A5036848171 @default.
• W4386753453 hasAuthorship W4386753453A5037677450 @default.
• W4386753453 hasAuthorship W4386753453A5044972820 @default.
• W4386753453 hasAuthorship W4386753453A5048855238 @default.
• W4386753453 hasAuthorship W4386753453A5050042851 @default.
• W4386753453 hasAuthorship W4386753453A5057146015 @default.
• W4386753453 hasAuthorship W4386753453A5060661714 @default.
• W4386753453 hasAuthorship W4386753453A5063795761 @default.
• W4386753453 hasAuthorship W4386753453A5074756323 @default.
• W4386753453 hasAuthorship W4386753453A5088582666 @default.
• W4386753453 hasBestOaLocation W43867534531 @default.
• W4386753453 hasConcept C121608353 @default.
• W4386753453 hasConcept C126322002 @default.
• W4386753453 hasConcept C126894567 @default.
• W4386753453 hasConcept C141071460 @default.
• W4386753453 hasConcept C143998085 @default.
• W4386753453 hasConcept C207103383 @default.
• W4386753453 hasConcept C2776694085 @default.
• W4386753453 hasConcept C2777381376 @default.
• W4386753453 hasConcept C2777701055 @default.
• W4386753453 hasConcept C2778283404 @default.
• W4386753453 hasConcept C2780057760 @default.
• W4386753453 hasConcept C2780352672 @default.
• W4386753453 hasConcept C2780739268 @default.
• W4386753453 hasConcept C2911057145 @default.
• W4386753453 hasConcept C3019882237 @default.
• W4386753453 hasConcept C44249647 @default.
• W4386753453 hasConcept C71924100 @default.
• W4386753453 hasConceptScore W4386753453C121608353 @default.
• W4386753453 hasConceptScore W4386753453C126322002 @default.
• W4386753453 hasConceptScore W4386753453C126894567 @default.
• W4386753453 hasConceptScore W4386753453C141071460 @default.
• W4386753453 hasConceptScore W4386753453C143998085 @default.
• W4386753453 hasConceptScore W4386753453C207103383 @default.
• W4386753453 hasConceptScore W4386753453C2776694085 @default.
• W4386753453 hasConceptScore W4386753453C2777381376 @default.
• W4386753453 hasConceptScore W4386753453C2777701055 @default.
• W4386753453 hasConceptScore W4386753453C2778283404 @default.
• W4386753453 hasConceptScore W4386753453C2780057760 @default.
• W4386753453 hasConceptScore W4386753453C2780352672 @default.
• W4386753453 hasConceptScore W4386753453C2780739268 @default.
• W4386753453 hasConceptScore W4386753453C2911057145 @default.
• W4386753453 hasConceptScore W4386753453C3019882237 @default.
• W4386753453 hasConceptScore W4386753453C44249647 @default.
• W4386753453 hasConceptScore W4386753453C71924100 @default.
• W4386753453 hasLocation W43867534531 @default.
• W4386753453 hasLocation W43867534532 @default.
• W4386753453 hasOpenAccess W4386753453 @default.

• next